Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MYSTICS-RCT: Methotrexate as second-line therapy for steroid-resistant or relapsed cardiac sarcoidosis
jRCTs051230077Completed
- Start
- Jul 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised trial in cardiac sarcoidosis (CS) and sarcoidosis comparing Prednisolone + methotrexate with Increased-dose prednisolone (2 arms). Started Jul 2023; status: completed.
02
Drugs
methotrexateprednisolone
03
Conditions
cardiac sarcoidosis (CS)sarcoidosis
Beyond the preview
Go deeper on jRCTs051230077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051230077.